$ARGX

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

Original reporting
Published Aug 26, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More — source image
Decision brief

The 30-second read

$ARGXBullishMed
01

Why it matters

These rating changes provide new actionable signals for traders, though impact varies by company.

02

Market read

Rating updates can cause short-term price moves and influence sector sentiment.

03

What to watch

Potential earnings season volatility could outweigh rating impact.

Relevance 7/10Novelty 7/10Timing: today

Background

The article compiles fresh analyst upgrades, downgrades, and initiations across several US-listed companies.

Company-level read

Ticker impact

$ARGXBullishMedium confidence
Context

ARGX was upgraded to Buy with a higher target price, indicating fresh positive analyst sentiment.

Expected impact

potential upside of 5-10%

Evidence & confidence

Analyst raised target and rating, suggesting improved outlook.

$DTMBullishMedium confidence
Context

DTM received an Outperform upgrade and a higher price target.

Expected impact

possible 3-7% gain

Evidence & confidence

Rating upgrade signals better earnings expectations.

$NEOGBullishMedium confidence
Context

NEOG was upgraded to Overweight with a modest target increase.

Expected impact

estimated 2-5% rise

Evidence & confidence

Higher rating reflects stronger growth prospects.

$SEDGBullishMedium confidence
Context

SEDG was raised to Buy with a higher target price.

Expected impact

potential 4-8% upside

Evidence & confidence

Analyst confidence increased, implying better performance.

$DKSBearishMedium confidence
Context

DKS was downgraded to Hold from Buy, lowering its target price.

Expected impact

possible 3-6% decline

Evidence & confidence

Reduced rating signals weaker outlook.

$EPAMBearishMedium confidence
Context

EPAM was cut to Neutral from Overweight, with a lower target.

Expected impact

estimated 2-5% drop

Evidence & confidence

Analyst lowered expectations.

$GDDYBearishMedium confidence
Context

GDDY was downgraded to Neutral from Overweight, target reduced.

Expected impact

possible 2-4% decline

Evidence & confidence

Weaker rating reflects concerns.

$INTUBearishMedium confidence
Context

INTU was cut to Neutral from Buy, with a lower target price.

Expected impact

potential 3-6% fall

Evidence & confidence

Analyst reduced confidence in growth.

Market effects

Analyst rating changes may affect tech and consumer discretionary sectors.

US market sentiment could shift slightly as multiple stocks receive new guidance.

Limited to US-listed equities; no direct global macro impact.

Counterpoint

Some upgrades may be premature given broader market volatility.

Key entities

  • UBS

    Provided upgrades for ARGX and SEDG.

  • Wolfe Research

    Upgraded DT Midstream.

  • Truist Financial

    Downgraded DKS and initiated AXGN.

Related articles

High

Argenx shares plunge 16% after Sjögren’s drug trial halted

Argenx shares dropped 16% after halting a Phase 3 trial of efgartigimod for Sjögren’s disease due to unlikely success. The independent committee recommended stopping the study as it wouldn't meet the primary endpoint. The company plans to analyze the data further. Efgartigimod is approved for other conditions in Japan.

$ARGXHigh

Why is argenx stock plunging today?

argenx SE (ARGX) stock fell 15.7% to €707.4 after terminating its Phase 3 UNITY study for efgartigimod in Sjögren’s disease due to failure to meet the primary endpoint. The company also reported positive Phase 2 results for its FB102 asset in celiac disease, but this did not offset the decline. The broader market and biotech sector were also under pressure.

$ARGXMed

argenx FB102 meets Phase 2 celiac endpoint

Argenx SE reported that its FB102 antibody met the primary endpoint in a Phase 2 celiac disease trial, showing statistically significant improvement over placebo. The company plans to advance the drug into Phase 3 development. Argenx's shares closed at US$928.44 on Wednesday, prior to the announcement. The trial measured intestinal damage, and the company noted a consistent safety profile. Argenx reported US$1.5 billion in Q2 product sales and US$472 million in profit.